PD-1/VEGF三抗崛起

药智网
Jul 09

随着康方生物依沃西挑战PD-1单抗成功,肿瘤免疫疗法(IO)快速迭代至2.0时代,PD-(L)1/VEGF双抗受到MNC抢购,而PD-(L)1/VEGF三特异性抗体也逐渐成为研发热潮,预示着肿瘤治疗正加速向多靶点协同方向演进。近日,基石药业宣布,其自主研发的潜在同类首创/同类最佳的CS2009(PD-1/VEGF/CTLA-4三特异性抗体)最新临床进展。该药具有均衡的单价PD-1和CTLA-4结合...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10